Page results
-
UCLH has formed a partnership with the Business Design Centre in Islington to deliver a second COVID-19 large scale vaccination centre.
-
A study at UCLH has found a combination treatment of immunotherapy with an experimental drug may reverse a cancer’s resistance to immunotherapy – making the cancer sensitive to treatment again.
-
How we use your information at UCLH: what you need to know
-
The High Court has today ruled in favour of a judicial review claim which means children and young people may not be able to consent to hormone-blocking treatment in cases of gender dysphoria.
-
CT Colonography bowel preparation and diet sheet patient information leaflet
-
Congratulations to the winners and finalists of this year’s Celebrating Excellence Awards, our annual celebration of the extraordinary work of our staff and volunteers.
-
Abbott are running free virtual education sessions for those using the Libre 2 sensors. These sessions are for those new to Libre 2, existing users, friends, family or carers.
-
I worked as a senior directorate accountant in finance in the NHS across a wide range of directorates, both corporate and clinical areas, working closely with these directorates on their financial plans, monitoring and forward planning.
-
COVID-19 vaccines are effective for most cancer patients but the level of protection offered by vaccines against infection, hospitalisation and death is lower compared with the general population and also wanes more quickly, according to a study in which UCLH participated.
File results
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology
-
FOI/2022/0577 - Injuries relating to e-scooters, cycling and moterbikes